Similarly, the treatment of human esophageal adenocarcinoma cells with sPLA2 inhibitor attenuates the expression of ICAM-1 [173] and decreases viability and proliferation of this type of cancer cell [174]. This evidence concerns the gene PLA2G2A and cancer.